Other causes include toxins within the brain, autoimmune disease, and infections, which include meningitis.Since the basal ganglia often have many connections with the frontal lobe of the brain, hyperkinesia can be associated with neurobehavioral or neuropsychiatric disorders such as mood changes, psychosis, anxiety, disinhibition, cognitive impairments, and inappropriate behavior.In children, primary dystonia is usually inherited genetically. Secondary dystonia, however, is most commonly caused by dyskinetic cerebral palsy, due to hypoxic or ischemic injury to the basal ganglia, brainstem, cerebellum, and thalamus during the prenatal or infantile stages of development. Chorea and ballism can be caused by damage to the subthalamic nucleus. Chorea can be secondary to hyperthyroidism. Athetosis can be secondary to sensory loss in the distal limbs; this is called pseudoathetosis in adults but is not yet proven in children. Diagnosis
Definition
There are various terms which refer to specific movement mechanisms that contribute to the differential diagnoses of hyperkinetic disorders. As defined by Hogan and Sternad, "posture" is a nonzero time period during which bodily movement is minimal. When a movement is called "discrete," it means that a new posture is assumed without any other postures interrupting the process. "Rhythmic" movements are those that occur in cycles of similar movements. "Repetitive," "recurrent," and "reciprocal" movements feature a certain bodily or joint position that occur more than once in a period, but not necessarily in a cyclic manner.Overflow refers to unwanted movements that occur during a desired movement.
While phenazopyridine has never been shown to cause cancer in humans, evidence from animal models suggests that it is potentially carcinogenic. Pregnancy
This medication is pregnancy category B. This means that the medication has shown no adverse events in animal models, but no human trials have been conducted. It is not known if phenazopyridine is excreted in breast milk. Pharmacokinetics
The full pharmacokinetic properties of phenazopyridine have not been determined. It has mostly been studied in animal models, but they may not be very representative of humans. Rat models have shown its half-life to be 7.35 hours, and 40% is metabolized hepatically (by the liver). Mechanism of action
Phenazopyridines mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. Hydroxylation is the major form of metabolism in humans, and the azo bond is usually not cleaved. On the order of 65% of an oral dose will be secreted directly into the urine chemically unchanged. Brand names
In addition to its generic form, phenazopyridine is distributed under the following brand names:

References
External links
Information about phenazopyridine from the US National Library of Medicine
Interstitial Cystitis Association
American Urological Association